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Abstract  
Background Osteoarthritis is a common degenerative musculoskeletal disease of synovial joints. It is 
characterised by a metabolic imbalance resulting in articular cartilage degradation, reduced 
elastoviscosity of synovial fluid and an altered chondrocyte phenotype. This is often associated with 
reduced mobility, pain and poor quality of life. Subsequently, with an ageing world population, 
osteoarthritis is of increasing concern to public health. Nuclear magnetic resonance (NMR) 
spectroscopy can be applied to characterise the metabolomes of biofluids, determining changes 
associated with osteoarthritis pathology, identifying potential biomarkers of disease and alterations 
to metabolic pathways.  
Sources of Data A comprehensive search of PubMed and Web of Science databases using 
combinations of the following keywords: ‘NMR Spectroscopy’, ‘Blood’, ‘Plasma’, ‘Serum’, ‘Urine’, 
‘Synovial Fluid’ and ‘Osteoarthritis’ for articles published from 2000-2020.  
Areas of Agreement The number of urine metabolomics studies using nuclear magnetic resonance 
spectroscopy to investigate osteoarthritis is low, whereas the use of synovial fluid is significantly 
higher. Several differential metabolites have previously been identified and mapped to metabolic 
pathways involved in osteoarthritis pathophysiology.  
Areas of Controversy Conclusions are sometimes conservative or overinflated, which may reflect the 
variation in reporting standards. Nuclear magnetic resonance metabolic experimental design may 
require further consideration, as do the animal models used for such studies.  
Growing Points There are various aspects which require improvement within the field. These include;  
stricter adherence to the Metabolomics Standards Initiative, inclusive of the standardisation of 
metabolite identifications; increased utilisation of integrating NMR metabolomics with other ‘omic’ 
disciplines; and increased deposition of raw experimental files into open access online repositories, 
allowing greater transparency and enabling additional future analyses. 
Areas Timely for Developing Research Overall, this research area could be improved by the inclusion 
of more heterogeneous cohorts, reflecting varying osteoarthritis phenotypes, and larger group sizes 
ensuring studies are not underpowered. To correlate local and systemic environments, the use of 
blood for diagnostic purposes, over the collection of synovial fluid, requires increased attention. This 
will ultimately enable biomarkers of disease to be determined that may provide an earlier diagnosis, 







Figure 1- Characteristic molecular changes observed in an osteoarthritic joint. The knee joint is shown as an 
example. 
 
Osteoarthritis (OA) is a common, progressive degenerative musculoskeletal pathology of synovial 
joints (1) (Figure 1). OA is inherently the result of an imbalance of catabolic and anabolic processes, 
often associated with disability, reduced mobility, pain and significant economic loss worldwide (2, 3). 
It is of increasing concern in our ageing population, with 80% of over 65-year olds worldwide being 
diagnosed with the condition (4). OA is a complex heterogeneous condition of multiple causative 
factors), including mechanical, genetic, metabolic and inflammatory pathway involvement, with a 
non-functional joint the shared endpoint (3, 5). In a research environment, OA is often studied using 
models, such as genetic, biomechanical, inflammatory and surgical (6), resulting in various OA 
phenotypes. There are cellular and molecular mechanisms of initiation and progression, resulting in 
loss of articular cartilage, reduced elastoviscosity of synovial fluid, thickening of subchondral bone, as 
well as joint space narrowing and osteophyte formation (7). Fundamentally, OA is a result of an 
imbalance in cartilage and bone remodelling. Further to this, calcified regions of cartilage are known 
to increase in volume and the synovium often experiences inflammation, fibrosis and vascularisation, 
resulting in clinical symptoms such as stiffness, pain and decreased range of motion (7). 
 
Currently, OA is predominantly diagnosed through clinical examination and radiographic imaging, and 
is therefore predominantly diagnosed during later disease stages. With no disease modifying drugs 
currently available, management of the condition is primarily symptomatic (3). To manage this 
debilitating condition more effectively it is hoped that ongoing interrogation of OA tissues at a 
molecular level will identify molecules and pathways which are altered during its pathogenesis 
and thus identify markers for earlier diagnosis and develop novel therapeutic targets.  
 
 
Biofluids used in Osteoarthritis Research 
Blood is commonly used clinically for diagnostic purposes. It is often utilised within research as its 
constituents reflect systemic change within the internal environment (8). It is reflective of biological 
functionality and physiology and can therefore be used to detect impairment resulting from disease. 
Additionally, it is regarded as an easily obtainable sample, involving minimal stress to the patient. 
Serum and plasma are amongst the most common biofluids studied in NMR metabolomics (9). 
However, collection tubes can affect the spectra obtained, introducing additional NMR signals due to 
contamination (9). Phelan et al found ethylenediaminetetraacetic acid (EDTA) tubes can result in 
spectral shifts and bind to various proteins within samples. Conversely, ‘Serum Z’ blood collection 
tubes were found to be most suited to NMR metabolomics (9). 
 
Urine is produced in the kidneys through filtration, reabsorption and secretion. As a result, urine 
contains end products of metabolic processes occurring within the body. It has been subject to 
biochemical analysis for more than 100 years and is used routinely in disease diagnosis (10). Urine is 
however chemically complex which can affect analysis and downstream interpretation (10).  
 
The synovial membrane, which lines the inner layer of the joint capsule, consists of a one-cell thick 
layer of synoviocytes within a hyaluronic acid and collagen matrix and is responsible for the production 
of synovial fluid (11). The membrane provides a pool of nutrients for surrounding tissues and a 
medium for cellular communication with the semi-permeable synovial membrane allowing passive 
protein transfer and synoviocytes secreting regulatory cytokines and growth factors (12). Due to the 
close relationship with articular tissues, both in terms of location and biological communication, 
synovial fluid provides a unique source of chemical information and holds great promise for biomarker 




Nuclear Magnetic Resonance (NMR) metabolomics has become a popular technique for the study of 
small molecules, known as metabolites, to understand the underlying pathophysiology of disease, 
enabling the identification of prospective biomarkers to inform diagnosis and therapeutic 
interventions. Metabolomics is the quantitative study of small molecules known as metabolites, 
identified within whole organisms, tissues, cells, biofluids and culture media (1). Metabolomics has 
been used to study multiple diseases associated with metabolic impairment, such as OA (13), 
alkaptonuria (14) and cancers (15). The two principal analytical tools to study metabolomics are 1H 
NMR spectroscopy and mass spectrometry (MS). The aim of each study and samples utilised often 
dictate the most appropriate analytic method to choose. MS is sensitive, quantitative, and can provide 
structural information, requiring relatively low volumes and can be easily coupled to a 
chromatographic separation. However, 1H NMR spectroscopy has the additional benefits of being non-
destructive, highly reproducible, with the ability to conduct targeted and untargeted analysis of both 
small and large molecules without any physical separation of the sample (16). 
 
1H NMR spectroscopy globally assesses the metabolome, producing individual spectra per sample that 
can be analysed. Sample spectra contain peaks specific to different hydrogen nuclei corresponding to 
various chemical groups within the small molecule metabolites. Hydrogen (1H) nuclei in distinct 
chemical groups differ from the 1H Larmor frequency, the result of atomic nuclei undergoing 
precessional motion when exposed to a magnetic field and electromagnetic radiation. Frequencies 
vary depending on electron shielding, resulting in a chemical shift frequency (measured in Hertz or 
parts per million) attributing to the varying position of peaks in the spectra (17). Peaks can be 
identified using reference databases such as the Human Metabolome Database (18), with the integral 
or area under each peak being directly proportional to the relative abundance of the metabolite within 
a sample.  
 
The technique relies on a phenomenon known as nuclear magnetic resonance, which occurs when the 
nuclei of certain atoms, such as hydrogen (in respective metabolites) are  in a static magnetic field and 
subjected to a short pulse of electromagnetic radiation (19). Atomic nuclei go from lower to higher 
energy states because of absorbing radiation (in the radio frequency range). This is known as selective 
absorption (resonance) whereby absorption only occurs if the frequency of radiation is equal to the 
Larmor frequency of the nuclei. The energy absorbed results in the induction of a voltage that can be 
detected by a coil wire, generating a current that oscillates at a given frequency (17). Once the 
electromagnetic radiation frequency pulse is removed, the oscillation will decay to zero, known as free 
induction decay (FID) (17, 19). A Fourier transformation (mathematical transformation) is applied to 
the FID signal to produce NMR spectra for analysis (20). 
 
Methods 
We performed a comprehensive search of PubMed and Web of Science databases using combinations 
of the following keywords: ‘NMR spectroscopy’, ‘Blood’, ‘Plasma’, ‘Serum’, ‘Urine’, ‘Synovial fluid’ and 
‘Osteoarthritis’ between the years 2000-2020. Our focus was on experimental studies and subsequent 
literature; therefore reviews were excluded.  
Results  
Biofluid - Blood  
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PTOA; Post Traumatic Osteoarthritis 
 
The use of blood has been reported in three OA studies over the last twenty years (Table 1). 
Experimental studies were used in all three papers, one using ovine and two murine models of OA, 
often surgically inducing producing a post traumatic OA model.  
 
Maher et al. (21) analysed serum from 36 sheep to explore the metabolic phenotype of surgically 
induced post traumatic OA subgroups, including a sham control, medial menisco-tibial ligament 
transection (MMLT) model and an anterior cruciate ligament (ACL) transection model. Dimethyl 
sulfone was present in increased abundance in the serum of the MMLT group. Conversely, 3-
methylhistidine was more abundant, and branched chain amino acids were less abundant in the ACLT 
group.  Differences in creatine serum levels identified were postulated to be a result of altered muscle 
metabolism, indicative of catabolic processes. Creatine was found in lower abundances in the MMLT 
group after 12 weeks, suggestive of decreased muscular metabolism.  It was found following post-
surgical procedures in all groups that serum levels of lactate decreased and acetate increased. Thus, 
observations made served to elucidate different metabolic phenotypes between models of OA, and 
the potential metabolic changes evident when using surgical models.  
 
A study by Maerz et al (22) on 36 rats investigated serum metabolome differences following the 
induction of OA through non-invasive ACL rupture (ACLR). Using NMR spectroscopy, 58 metabolites 
were identified. Acylcarnitines, tryptophan, glycine, carnosine, and D‐mannose accounted for some of 
the differentially abundant metabolites between groups. Acylcarnitines were attributed to altered 
energy production, as it is a fatty acid ester of L-carnitine, known to promote long chain fatty acid 
uptake into mitochondria via the carnitine shuttle (22). Low levels have been associated with immune 
and inflammatory conditions due to incomplete beta oxidation, resulting in inflammation through the 
NF-kB pathway (22). Tryptophan metabolism was postulated to be involved as a result of the 
identification of decreased L‐aspartic acid, 1‐phenylethylamine, and serotonin concentrations at 72 
hours, along with a decrease in L‐kynurenine, serotonin, and L‐aspartic acid at four weeks post 
induction. Proinflammatory pathways were hypothesised to be activated post-surgery because of 
reduced interleukin 17 suppression. In addition, glycine metabolism contributes to muscular fibrosis 
and has a regulatory purpose in collagen synthesis (22).  
 
In another study, Mickiewicz et al (23) analysed serum from 200 mice to quantify the effect of Erlotinib 
(tyrosine kinase inhibitor) treatment and the Integrin α1-Null Genotype on the serum metabolome of 
mice with surgically induced OA. Integrin α1 heterodimerizes with the beta 1 subunit to form a cell-
surface receptor for collagen and laminin. Increased expression of integrin α1β1 and inhibition of 
epidermal growth factor receptor signalling have previously been shown to protect the knee from 
spontaneous OA. NMR spectroscopy identified 64 metabolites, with five appearing to be differentially 
abundant, including increased levels of O-acetylcarnitine, dimethyl sulfone, 2-hydroxyisovalerate, 
butyrate, and trimethylamine N-oxide in the group with Erlotinib treatment and surgical OA. Dimethyl 
sulfone was attributed to anti-inflammatory mechanisms post-surgery. In addition, glutamine was 
identified as elevated in α1-Null mice compared to wild type, suggestive of protective properties, 
preventing reactive oxygen species induced apoptosis of chondrocytes (23). A decrease in serotonin 
was also reported, relating to tryptophan metabolism, which has been associated with OA progression 
in previous studies, such as in Maerz et al (22). 
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Urine as a biofluid is used less frequently in OA NMR metabolomic studies with only two published 
research papers in the last 20 years (Table 2). Urine samples were used by Lamers et al (24) to analyse 
the metabolome of Hartley guinea pigs with spontaneous OA. Lactic acid, malic acid, hypoxanthine 
and alanine were differentially abundant and attributed to altered purine metabolism and energy 
production. However, limited pathway analysis and biological context were provided regarding 
differentially abundant metabolites within this study. This was also noted across previous studies and 
may reflect the change in technology and processing software available for pathway analysis. A further 
study by Lamer et al (25) analysed urine samples from human patients diagnosed by radiographic 
images. In this study hydroxybutyrate, pyruvate, creatine and glycerol were found in greater 
abundance within urine from OA patients, attributed to a shift in energy production, promoting the 
utilisation of fats. Histidine and methylhistidine were in lower abundance in OA, implicating altered 
histidine metabolism. Additionally, histamine and histidine decarboxylase were identified in 
chondrocytes derived from OA cartilage. Lamer et al (25) emphasised the lack of distinction between 
the local and systemic environment when using systemic fluids for metabolic research and it was 
suggested that this could be accounted for by experimental design, ensuring sample types are clearly 
distinct to  the aims of the study,  particularly when considering diseases, such as OA, that have a 
predominantly localised phenotype.  
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ESOA; end stage osteoarthritis, OA; osteoarthritis, OC; osteochondrosis, RA; rheumatoid arthritis, and 
SF; synovial fluid. 
 
Synovial fluid is a popular biofluid in OA research, due to its close anatomical proximity to the diseased 
environment, reflecting local changes (35). Eleven papers were identified using synovial fluid to 
conduct NMR spectroscopy analysis (Table 3). Marshall et al used an experimental canine model of 
OA to ascertain the effect of potential therapeutic agents on the synovial fluid metabolome (32). They 
identified increased abundance of isoleucine and decreased abundance of glucose in the specified 
treatment groups compared to sham controls (Table 3). They also described that arthroscopically 
graded OA was often accompanied by increased acetate, glucose, hydroxybutyrate and amino acids.  
Increased acetate is a prominent marker of polymeric degradation of cartilage and synovial fluid 
whereas hydroxybutyrate was linked to the regulation of fatty acid metabolism (32). Interestingly, 
early NMR metabolomic studies did not conduct as rigorous statistical analysis and NMR spectra were 
compared qualitatively rather than quantitatively (30).  
 
Some large animal clinical studies have used equine synovial fluid to compare normal and OA joint 
metabolomes (13, 29). In one study lactate, alanine, glucose, acetate, pyruvate, citrate, creatine, 
glycerol and lipoproteins were differentially abundant, and found to be increased in OA (29). The 
group suggested increased lactate production was indicative of inflammation, while glycerol was 
reflective of fat metabolism. Creatinine has been implicated in muscle breakdown, which has been 
considered to reflect muscular breakdown in close proximity to diseased joints in OA (29). Acetate is 
a by-product of cartilage degradation and is regarded as a significant metabolite in OA 
pathophysiology (29). In a similar study, Anderson et al (13) identified a number of the same 
metabolites to be differentially abundant and present in higher concentrations. Glutamate, creatinine, 
glycine, phenylalanine, valine and glycyl proline were also identified in greater abundance in OA SF. 
Several of these differentially abundant metabolites related to processes such as extracellular matrix 
degradation. When analysing human clinical OA samples, Mickiewicz et al (30) found 11 of the 55 
metabolites identified to be differentially abundant between post-mortem and ante-mortem groups, 
including, creatine, o-acetylcarnitine, methionine, ethanol, hydroxybutyrate and malate. All of which 
were found to be decreased in the OA group. It should be noted that the groups are confounding to 
findings from this paper, as the metabolome of deceased individuals is significantly different to that 
of those living. An increase in fructose and citrate in OA joints was attributed to hypoxic conditions 
and a potential upregulation of glucose phosphate isomerase, known to catalyse glucose 6 phosphate. 
Decreased malate was also linked to an altered tricarboxylic acid cycle (TCA) and the dysregulation of 
energy production. Furthermore, a decrease in methionine in OA groups was regarded as indicative 
of it being utilised and converted into s-adenosylmethionine (30). These have been proposed to act as 
cartilage damage and inflammatory reducing factors (30). Mickiewicz et al (4) also conducted a study 
on an experimental model of OA in ovine species using ACL reconstruction. In this study metabolites 
such as isobutyrate, glucose, hydroxyproline and asparagine were differentially abundant. A decrease 
in hydroxyproline was indicative of an increase in collagen synthesis hypothesised to be in response 
to increased degradation (4). Furthermore, increased glucose abundance was related to impaired 
chondrocyte function, promoting degenerative changes through a disruption of dehydroascorbate 
transport into the cells. This resulted in an increase in reactive oxygen species and catabolic gene 
expression signalling pathways (4).  
 
Akhbari et al (26) conducted NMR analysis on human clinical samples of hip and knee OA and found 
citrate, n-acetylated molecules, glutamine and glycosaminoglycans to be differentially abundant in 
and in greater quantities in the knee group compared to hip. Citrate is an intermediate in the TCA 
cycle, as well as urea, amino acid and fatty acid metabolism (26). Altered energy production and 
oxidative metabolism have been regarded as characteristic of OA (26). Glutamine was associated with 
altered oxidative metabolism as well suppressing the formation of cytokines and protecting 
chondrocytes from heat stress. GAGs have also been regularly associated with cartilage breakdown 
(26). Anderson et al (27) observed differences between OA and rheumatoid arthritis (RA) in clinical 
human synovial fluid samples. They identified 32 differentially abundant metabolites between groups, 
including hydroxybutyrate, alanine, taurine and valine, which increased in abundance in OA. 
Interestingly, citrate and glutamine were also found to be increased, indicative of an altered TCA cycle 
and glycolysis. This was postulated to be due to the need for increased adenosine triphosphate for 
extracellular matrix (ECM) biosynthetic machinery to function due to increased demand for ECM 
production in OA joints due to increased matrix metalloproteinase degradation of cartilage. In 
addition, taurine metabolism was implicated in OA pathophysiology, correlating with subchondral 
bone sclerosis, a pathogenic change related to later stage OA and its severity.  
 
Discussion  
The number of NMR metabolomic studies of biofluids in OA has greatly increased since 2015 as the 
field has expanded and progressed rapidly with improved technologies and the increasing application 
of metabolomics. Authors of significant contribution include the Mickiewicz (4, 23 and 30) and Peffers 
(13, 27 and 33) groups. Many studies noted significant changes consistently in amino acids, pyruvate 
and creatine, with studies across all biofluids identifying a change in energy utilisation, through the 
increased involvement of lipid metabolism, while also identifying inflammatory processes. 
Metabolites consistently being identified in OA metabolomics research could now be investigated in 
a targeted way, using mechanistic experiments to further understand their role in OA 
pathophysiology.  
Synovial fluid has evolved to be the biofluid of preference when conducting OA research, due to its 
biology reflecting the local environment of the diseased joint, whereas urine and blood are systemic. 
The use of blood as a systemic biofluid, the collection of which is a less invasive procedure, has not 
yet increased sufficiently, and requires further investigation. Correlating findings between the local 
and systemic environment appears to be problematic due to significant confounding factors when 
considering the global biology of a patient, such as diet, lifestyle and co-morbidities. These variables 
are often controlled in studies using animal models but these models cannot fully replicate a realistic 
human biological environment. Additionally, the use of synovial fluid in research has been repeatedly 
replicated, providing scientific confidence in its use, when compared with other biofluids. Synovial 
fluid is favoured over urine, due to urine metabolites reflecting the global environment, rather than 
specific changes in the joint. Urine is also a source of end point metabolites, rather than intermediates 
that account for the dynamic processes occurring within the body.   
Similar conclusions with respect to metabolic alteration in OA are drawn repeatedly from studies 
identifying similar metabolic pathways and differential metabolites, elucidating some underlying 
mechanisms of OA pathophysiology.  However, studies are often not balanced in conclusions drawn, 
often not appropriately considering limitations, resulting in inflated conclusions being reported, 
without validation of metabolites using additional platforms or independent cohorts. The NMR 
metabolomic field has a limited publishing history compared to other ‘omics’ disciplines, such as 
proteomics, in the field of OA research. Studies are reported to varying degrees of quality, not always 
acknowledging relevant limitations to experimental design, such as the animal models used or the 
need for adequate controls. This has resulted in repeated similar studies, rather than research evolving 
to reflect the knowledge gained, although this is beginning to change.  Anderson et al (36) recently 
published protocols for optimisation of synovial fluid collection and processing for NMR 
metabolomics, providing the metabolomics community with evidence based suggestions, such as 
recommending synovial fluid should first be centrifuged to remove cellular material then immediately 
flash frozen in liquid nitrogen (36). As collection procedures and processing is particularly pivotal to 
the NMR metabolomics pipeline and can greatly affect the integrity of the sample and the metabolites 
identified, optimisation enables increased molecular identifications and improved technical 
reproducibility (36). These factors are therefore important to consider when designing NMR 
metabolomics studies, including sample collection for biobanks, in order to ensure samples are 
suitable for NMR analysis. It also exemplifies the benefits of building on research previously conducted 
and identifying areas for improvement, having a significant impact on the metabolomics community, 
supporting the need for standardisation of protocols, pipelines and ultimately quality of scientific 
reporting.  In addition, many studies are often underpowered, with very few power calculations being 
recorded in the literature.  
The systemic issue in the quality of metabolomics reporting has been previously addressed by the 
Metabolomics Society, publishing the Metabolomics Standards Initiative (MSI) in 2005 (37, 38). Here 
five working groups were established to determine best practice regarding metabolomic study 
pipelines: biological context metadata, chemical analysis, data processing, ontology and data 
exchange (35, 36 and 37). A series of papers were also published in 2007 with minimum reporting 
guidelines covering all areas of the metabolomics (38, 39). Constantine et al  suggested the most 
significant problem in the field was data analysis, with poor adherence to guidelines by the 
metabolomics community and a lack of a standard for analysing metabolomics data, despite this being 
addressed with the development of various software such as Metaboanalyst (39). As a result, a lack 
of standardisation has impaired the translational capacity, reproducibility and replicability of some 
metabolomic studies. 
 It has previously been reported within the literature that the use of silicon-based standards, such as 
trimethylsilyl propanoic acid (TSP) and sodium trimethylsilylpropanesulfonate (DSS), are inappropriate 
for use with protein-rich biofluids due to protein binding, e.g. albumins, resulting in a change in 
chemical shift or complete attenuation (40). However almost half of the studies investigating synovial 
fluid within this review used TSP or DSS as an internal standard. It is also inappropriate for blood serum 
or plasma studies to use such reference standards for the same reasons. Despite this all NMR studies 
of OA using blood identified in this review used TSP or DSS. It has been postulated that providing 
official pipelines for preparation and analysis, as well as journals adhering to community guidelines 
for published work may improve the field and its current state moving forward (39).   
NMR spectroscopy of OA biofluids has provided a source of evidence implicating metabolic changes 
involved in the pathophysiology, initiation and progression of disease. Further studies are required to 
quantify and validate such findings, while adhering to metabolomics community guidelines to ensure 
best practice. Consideration should be given to larger study sizes, to address the issue of 
underpowered studies, along with more heterogeneous populations of disease to account for the 
variable nature of OA. This will aid in moving the field forward in the pursuit of identifying conclusive 
biomarkers that may be used for diagnostic purposes whilst exploring metabolic pathways as potential 
therapeutic targets. Coupling metabolomics data with other omic technologies, such as 
transcriptomics and proteomics, in order to take a ‘multi omic’ approach is also required to advance 
the field further (41). This will enable biological integration and interaction between different 
biomolecules, layering understanding and accounting for the complexity of systems biology and the 
dynamic environment across species. The capacity of this approach was demonstrated by Anderson 
et al  who identified a panel of molecules of interest in equine OA stratification through proteomic 
and metabolomic integration (33). It would be preferable for raw data to be provided in 
supplementary material sections in order to encourage transparency in research, improving 
communication and clarity, as over half of the cited papers in this review did not publish raw data files, 
or upload to data repositories. The inclusion of this would allow for additional analysis to be 
conducted, including meta-analysis and multivariate analysis.  
Conclusion  
NMR spectroscopy of biofluids, such as serum, plasma, urine and synovial fluid, has provided further 
understanding of OA pathogenesis and has the capacity to enable biomarker identification. 
Subsequently this may allow researchers to detect early disease changes and to create specific 
therapeutics for OA. This can only be achieved with an increased uptake of metabolomics technologies 
in research, a standardised level of scientific reporting with respect to metabolomics and further 
exploration of the relationship between the local and global environment. We advocate the 
communication of best practice and robust experimental design to produce findings of significant 
impact that may change the scientific landscape of OA research.  
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